Tradestie Institutional Equity Comparison Engine

MBIO vs DARE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBIO Overall Edge

MBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mustang Bio, Inc. (MBIO) driven by superior Growth & Margin, Momentum & Technical while DARE counters with relative strength in Valuation. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DARE at 1.3x Forward P/E and -813.4% operating margin (+499.6% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DARE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DARE
MBIO N/M vs DARE 1.3x Fwd P/E
Growth & Margin Winner MBIO
Op Margin 0.0% vs -813.4% ยท YoY +0.0% vs +499.6%
Momentum & Technical Winner MBIO
1Y -67.4% vs -69.1% ยท 52W Pos 4% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
1M Return +4.86%
1Y Return -67.38%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-11.13% 1D
Market Cap $12.9M
1M Return -19.38%
1Y Return -69.09%
Forward P/E 1.3x
Unified AI Score
45.7 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBIO -67.38% DARE -69.09% Spread: +1.71 pp (MBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBIO TTM Op. Margin: 0.0% DARE TTM Op. Margin: -813.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs DARE. Trailing 12-month operating profitability (MBIO 0.0% vs DARE -813.4%) and valuation multiples (MBIO N/M vs DARE 1.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBIO (3) vs DARE (5)
Institutional Metric MBIO DARE Criterion Row Winner
Market Capitalization Scale $3.2M $12.9M Larger Scale Tie
Trailing P/E Ratio Valuation N/M 1.3x Lower Multiple DARE
Forward P/E Ratio Valuation N/M 1.3x Lower Multiple DARE
Revenue Growth (YoY) Growth +0.0% +499.6% Higher Growth DARE
Operating Margin (TTM) Profitability 0.0% -813.4% Higher Margin MBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -43.1% -2543.1% Higher ROE MBIO
52-Week Range Position Momentum 4% ($0โ€“$1) 0% ($1โ€“$4) Stronger Trend MBIO
Beta / 30D Volatility Risk Regime 0.66ฮฒ ยท 86% Vol 1.40ฮฒ ยท 62% Vol Lower Realized Risk DARE
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 45.7 / 100 (HOLD) Higher Composite DARE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBIO vs DARE Buy Guide
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DARE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DARE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBIO nor DARE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.